Steve Schonfeld Schonfeld Strategic Advisors
Steve Schonfeld is the founder of Schonfeld Strategic Advisors, a multi-manager investment firm with roots in proprietary trading. Schonfeld allocates capital across quantitative and discretionary strategies with an emphasis on risk controls and diversification of return streams. The firm is a major name in the multi-strategy hedge fund landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$11.5M |
| 2 |
Eli Lilly
LLY
|
+$10.9M |
| 3 |
UnitedHealth
UNH
|
+$9.37M |
| 4 |
HOLX
Hologic
HOLX
|
+$8.36M |
| 5 |
AbbVie
ABBV
|
+$7.88M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$14.1M |
| 2 |
Dell
DELL
|
+$10.7M |
| 3 |
Molson Coors Class B
TAP
|
+$9.81M |
| 4 |
Netflix
NFLX
|
+$8.78M |
| 5 |
Bank of N.T. Butterfield & Son
NTB
|
+$8.31M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.58% |
| 2 | Consumer Discretionary | 15.85% |
| 3 | Technology | 13.94% |
| 4 | Communication Services | 9.51% |
| 5 | Financials | 8.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
601
KeyCorp
KEY
$23.3B
| – | – |
-17,472
| Closed | -$213K |
|
602
CarMax
KMX
$8.82B
| – | – |
-37,516
| Closed | -$2M |
|
603
Lennar Class A
LEN
$21B
| – | – |
-25,174
| Closed | -$1.01M |
|
604
Liberty Latin America Class C
LILAK
$1.64B
| – | – |
-32,203
| Closed | -$773K |
|
605
LKQ Corp
LKQ
$6.52B
| – | – |
-52,101
| Closed | -$1.85M |
|
606
Cheniere Energy
LNG
$57.3B
| – | – |
-4,579
| Closed | -$200K |
|
607
Lam Research
LRCX
$393B
| – | – |
-58,400
| Closed | -$553K |
|
608
Matsons
MATX
$6.66B
| – | – |
-27,401
| Closed | -$1.09M |
|
609
McKesson
MCK
$100B
| – | – |
-5,329
| Closed | -$889K |
|
610
Mohawk Industries
MHK
$9.23B
| – | – |
-6,213
| Closed | -$1.25M |
|
611
Monster Beverage
MNST
$93.6B
| – | – |
-241,920
| Closed | -$2.96M |
|
612
Molina Healthcare
MOH
$10.5B
| – | – |
-11,457
| Closed | -$668K |
|
|
MPT
613
Medical Properties Trust
MPT
$2.46B
| – | – |
-50,000
| Closed | -$739K |
|
614
Neurocrine Biosciences
NBIX
$15.5B
| – | – |
-5,419
| Closed | -$274K |
|
615
Nabors Industries
NBR
$1.37B
| – | – |
-392
| Closed | -$238K |
|
616
Minerva Neurosciences
NERV
$231M
| – | – |
-2,560
| Closed | -$289K |
|
617
Nektar Therapeutics
NKTR
$2.53B
| – | – |
-1,454
| Closed | -$375K |
|
618
NetApp
NTAP
$37.7B
| – | – |
-6,000
| Closed | -$215K |
|
|
619
Bank of N.T. Butterfield & Son
NTB
$2.3B
| – | – |
-335,525
| Closed | -$8.31M |
|
620
Nutanix
NTNX
$18.3B
| – | – |
-89,400
| Closed | -$3.31M |
|
621
Nu Skin
NUS
$231M
| – | – |
-12,580
| Closed | -$815K |
|
622
NVIDIA
NVDA
$5.2T
| – | – |
-884,200
| Closed | -$1.51M |
|
623
Novartis
NVS
$302B
| – | – |
-23,888
| Closed | -$1.69M |
|
624
Newell Brands
NWL
$2.59B
| – | – |
-71,059
| Closed | -$3.74M |
|
625
New York Times
NYT
$10.6B
| – | – |
-20,672
| Closed | -$247K |
|
Similar funds
Steve Schonfeld's Q4 2016 Portfolio in Review
As of Q4 2016, Steve Schonfeld held 720 positions worth $772M, up 31% from $589M the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Steve Schonfeld deployed $177M of net new capital in Q4 2016, opening 321 new positions and adding to 119 existing holdings. Its largest new stake was Eli Lilly: 146,398 shares worth $10.8M.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, up from 12% a quarter earlier, followed by Consumer Discretionary and Technology.
On the sell side, the largest reduction was Amazon, an estimated $14.1M trimmed.
- Steve Schonfeld's largest Q4 2016 buy was Eli Lilly: 146,398 shares worth $10.8M.
- Steve Schonfeld added most to Amgen in Q4 2016, an estimated $11.5M increase.
- Steve Schonfeld's biggest Q4 2016 reduction was Amazon, cutting an estimated $14.1M.
- Steve Schonfeld fully exited Bank of N.T. Butterfield & Son in Q4 2016, selling an estimated $8.31M.
- Steve Schonfeld's ten largest holdings make up 12% of its $772M portfolio in Q4 2016.
- Steve Schonfeld opened 321 new positions and closed 193 in Q4 2016.
- Steve Schonfeld's portfolio value rose 31% quarter-over-quarter to $772M.
Based on Schonfeld Strategic Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.